Google: Piper inovio price target...came out roughly two hours ago (8:30)
Piper Jaffray maintained an Overweight rating on Inovio Pharmaceuticals (NYSE: INO) and raised its price target to $6.50 (from $3.50).
I've sold all of my holdings and put every penny in INO.
I am a high school Spanish/Japanese teacher. I do not make a lot of money but I love what I do.
That being said I still plan on retiring early once INO takes off...then I will take off on an endless around the world vacation. I plan on learning Chinese. I also plan on helping some charities in my area.
6 years from now I will be 40 and a millionaire. :-)
Best of luck to us all and most importantly to those who will benefit from Inovio's drugs.
May 15th...we'll find out about our new BLUE CHIP investor(s)!!! 5 bucks soon. Not pumping, just restating what some doctor named Joeseph Kim said...and by the way, he owns over 11 million shares.
For an AWESOME group of INOVIO investors check out Inovio's Facebook group. There are two but the one you want to be apart of is Inovio Parmaceuticals, DNA through electroportation
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and raised his price target on Inovio Pharmaceuticals (NYSE: INO) from $3 to $4, citing interesting IL-33 results and the addition of HebB to their model.